Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant

Yucheol Cheong1, Minjin Kim2, Jina Ahn3, Hana Oh1, Jongkwan Lim1, Wonil Chae1, Seung Won Yang1, Min Seok Kim2, Ji Eun Yu1, Sanguine Byun1*, Yo Han Jang4,5* and Baik Lin Seong6,7*

1 Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea, 2 Graduate Program in Biomaterials Science and Engineering, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea, 3 The Interdisciplinary Graduate Program in Integrative Biotechnology & Translational Medicine, Yonsei University, Incheon, South Korea, 4 Department of Biological Sciences and Biotechnology Major in Bio-Vaccine Engineering, Andong National University, Andong, South Korea, 5 Vaccine Industry Research Institute, Andong National University, Andong, South Korea, 6 Department of Microbiology, College of Medicine, Yonsei University, Seoul, South Korea, 7 Vaccine Innovative Technology Alliance (VITAL)-Korea, Yonsei University, Seoul, South Korea

Vaccine adjuvants from natural resources have been utilized for enhancing vaccine efficacy against infectious diseases. This study examined the potential use of catechins, polyphenolic materials derived from green tea, as adjuvants for subunit and inactivated vaccines. Previously, catechins have been documented to have irreversible virucidal function, with the possible applicability in the inactivated viral vaccine platform. In a mouse model, the coadministration of epigallocatechin-3-gallate (EGCG) with influenza hemagglutinin (HA) antigens induced high levels of neutralizing antibodies, comparable to that induced by alum, providing complete protection against the lethal challenge. Adjuvant effects were observed for all types of HA antigens, including recombinant full-length HA and HA1 globular domain, and egg-derived inactivated split influenza vaccines. The combination of alum and EGCG further increased neutralizing (NT) antibody titers with the corresponding hemagglutination inhibition (HI) titers, demonstrating a dose-sparing effect. Remarkably, EGCG induced immunoglobulin isotype switching from IgG1 to IgG2a (approximately >64–700 fold increase), exerting a more balanced TH1/TH2 response compared to alum. The upregulation of IgG2a correlated with significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) function (approximately 14 fold increase), providing a potent effector-mediated protection in addition to NT and HI. As the first report on a novel class of vaccine adjuvants with built-in virucidal activities, the results of this study will help improve the efficacy and safety of vaccines for pandemic preparedness.

Keywords: EGCG, adjuvant, IgG isotype switching, influenza, ADCC

INTRODUCTION

Classical vaccines composed of whole virions or bacteria, such as live attenuated or inactivated vaccines, have inherent immune-stimulating effects exerted by various components, including proteins, lipids, and nucleic acids. However, new generation vaccine platforms such as subunit vaccines or nucleic acid (e.g. DNA) vaccines are relatively less immunogenic and, thus, require
appropriate adjuvants to enhance their immunogenicity (1, 2). Since most vaccines are used in healthy people for prophylactic purposes, both vaccines and adjuvants are required to demonstrate a high level of safety and tolerability. Many factors should be taken into account for the proper selection of adjuvants, including the vaccine type, desired immune response, administration route, and target population (2–5). Presently, licensed or tested adjuvants can be classified into two groups: 1) immunomodulatory molecules that directly activate innate immune receptors including Toll-like receptors (TLRs), such as poly(I:C) and monophosphoryl lipid (MPL), and 2) particulate formulation systems that promote antigen delivery and uptake, such as aluminum salts, MF59, and liposomes (6). In addition, the combination of immunomodulating molecules and particulate formulations has been extensively investigated for various vaccines. For example, AS adjuvant series such as AS01, AS03, and AS04 are currently used in human vaccines for various infectious diseases, such as influenza, herpes zoster, and hepatitis B virus (7–9).

Among the currently licensed vaccine adjuvants, aluminum salts (alum) have been most widely used in human vaccines for >80 years. Although alum has proven to be effective and safe for humans, some limitations have been noted. Alum poorly induces cell-mediated immunity (CMI) or T cell responses (10); moreover, alum-mixed vaccines cannot be frozen and dried, limiting their long-term storage (11). Similarly, oil-in-water emulsions, such as MF59, are applied with other substances as TLR agonists to establish more potent CMI (12, 13). CMI plays a pivotal role in initiating protection against viral infections and the subsequent elimination of virus-infected cells (14). While subunit vaccines primarily activate T helper 2 (Th2) cells, live attenuated vaccines or subunit vaccines in combination with specific adjuvants trigger T helper 1 (Th1) cells that induce robust CMI (15). Th1 cells induce CMI by secreting interferon-gamma and activating B cells to produce immunoglobulin (Ig) G1 and IgG3 antibodies in humans (IgG2a and IgG2b in mice) (16, 17), which are closely related to the antibody-dependent cellular cytotoxicity (ADCC) function; Fcγ receptors of effector cells such as natural killer cells recognize the Fc region of IgG1 and IgG3 antibodies (IgG2a and IgG2b in mice) bound to infected cells (18, 19). Most adjuvants developed after alum have been shown to induce Th1 immune responses, with some inducing both Th1 and Th2 immune responses (2, 20–23), suggesting that the balanced induction of Th1 and Th2 immune responses is highly desirable for vaccine efficacy.

Various types of biomaterials such as microbial MPL (21), cholera toxin subunit B (24), plant-derived QS-21 (23) and synthetic CpG (22) are used as adjuvants to induce robust CMI. The saponin QS-21, a triterpinoid material isolated from Quillaja saponaria tree bark, induces balanced Th1/Th2 immune responses and is used as an adjuvant for the varicella zoster virus vaccine (8) and coronavirus disease 2019 (COVID-19) vaccine (25, 26). However, due to adverse side effects, such as hemolysis and pain at the injection site, as well as limited supply, practical alternatives are needed (27–29).

Green tea (Camellia sinensis) catechins are polyphenolic compounds that exhibit a variety of biological activities, including antioxidant, antitumor, and antimicrobial effects (30–32). The most abundant catechin epigallocatechin-3-gallate (EGCG) (Figure 1A) has been shown to demonstrate antiviral activity against a wide range of viruses through diverse mechanisms (33, 34). Structure–activity relationships revealed that the 3-galloyl group of the catechin skeleton plays an important role in virucidal function (33, 34). The potent irreversible virucidal effect of catechins was harnessed for the generation of inactivated vaccines, which are highly immunogenic and provide complete protection against lethal challenges (35). The outbreak of novel swine influenza in 2009 prompted the vaccine manufacturers to consider recombinant vaccine that would be supplied in a timely manner. The present study examined whether EGCG can serve as a novel vaccine adjuvant for a subunit/split influenza vaccine. The adjuvanticity of EGCG was evaluated primarily using recombinant influenza hemagglutinin (HA) in a mouse model. In addition, immune responses elicited by EGCG-adjuvanted HA were also characterized in terms of antibody profile and antibody effector functions such as ADCC. Our study is the first report on a novel class of vaccine adjuvants that have both virucidal and adjuvant activities. With well-documented health benefits and immune stimulation, EGCG is an attractive option for the development of effective and safe vaccines for pandemic preparedness.

MATERIALS AND METHODS

Green Tea Extract and EGCG

Green tea extract (GT) was provided by Amore-Pacific Co. (Seoul, Republic of Korea) as previously described (34). It comprised caffeine (5.48%), gallic acid (0.22%), galacteatin (1.95%), epigallocatechin (10.22%), catechin (0.5%), EGCG (9.11%), epicatechin (2.51%), and gallatechin gallate (0.88%), as determined by high-performance liquid chromatography (HPLC). Purified EGCG (98%, powder) was purchased from Changsha Sunfull Biotech (Changsha, China). The GT and EGCG solutions were prepared by adding distilled water to the powder.

Cell Line, Influenza Virus, Recombinant Protein, and Antigens

Madin–Darby Canine Kidney (MDCK, ATCC CCL-34) cells were cultured in minimum essential medium (MEM, HyClone, Logan, UT, U.S.) supplemented with 10% fetal bovine serum (HyClone). Influenza A/Puerto Rico/8/34 (H1N1) (PR8), A/Seoul/Y-1/2009 (H1N1), A/Philippines/2/82 (H3N2), B/Shanghai/361/2002, and B/Brisbane/60/2008 viruses were propagated in chicken embryos and stored at –80°C until further use. Recombinant HA full-length proteins derived from PR8 were purchased from Sino Biological (Beijing, China). The recombinant HA globular domains (GDs) of PR8 were expressed and purified as described previously (36). Briefly, the proteins were fused with the mouse RNA-interaction domain (RID) of lysyl-tRNA synthetase (LysRS) for soluble expression in Escherichia coli. The recombinant HA stalk domains (STs) of
PR8 were expressed by fusion with LysRS and purified as described previously (37). The formalin-inactivated influenza virus (FAiV) was prepared by mixing 0.1% (v/v) of formaldehyde with 2 × 10⁶ PFU of influenza virus (A/PR/8/34), and the mixtures were incubated for 24 h at room temperature (RT, approximately 20-25°C). Human papillomavirus (HPV) 16 L1 virus-like particle (VLP) antigens were fused with the human RID of LysRS for soluble expression in E. coli. Tetravalent seasonal influenza vaccine, Kovax Flu Tetra PF (2018) (Kovax), was purchased from Korea Vaccine Inc (Seoul, Republic of Korea). All antigens were diluted in PBS. Alum, which contains an aqueous solution of aluminum hydroxide and magnesium hydroxide, was purchased from Thermo Fisher Scientific (Imject Alum, Waltham, MA, U.S.).

Animal Experiments
All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the International Vaccine Institute (IVI, Seoul, Republic of Korea) (IACUC PN 2017-019, IACUC PN 2018-008, and IACUC PN 2019-007) and carried out in the ABSL-2 facility of IVI. Six-week-old female BALB/c mice (Orient Bio, Seongnam, Republic of Korea) were vaccinated with various additives via IM or IP routes. Only FAiV with or without EGCG was injected via IP route. Blood was collected from vaccinated mice by retro-orbital bleeding under anesthesia. After vaccination, the mice were challenged by intranasal infection with the PR8 virus under anesthesia. Mice that lost >25% body weight were euthanized.
Enzyme-Linked Immunosorbent Assay (ELISA) for Antibody (IgG, IgG1, and IgG2a) Titers

ELISA was performed to estimate the HA-specific antibodies in mouse sera. Ninety-six-well plates were coated with 10^5 PFU of PR8 viruses or 0.05 μg of HA GD or ST proteins per well. The plates were incubated with two-fold serially diluted sera for 1 h at RT after blocking. After washing, the plates were incubated with Horseradish peroxidase (HRP)-conjugated antimouse IgG, IgG1, or IgG2a antibodies for 1 h at RT. After washing, the plates were incubated with Tetramethylbenzidine (TMB) solution for 30 min at RT. The reaction was stopped by adding 2N H_2SO_4 solution, and the optical density was measured at 450 nm using an ELISA reader.

Hemagglutination Inhibition Assay and Plaque Reduction Neutralization Test

Hemagglutination inhibition (HI) assay and plaque reduction neutralization test (PRNT) were performed to measure the neutralizing antibody titers. For HI assay, sera were pretreated with a receptor-destroying enzyme overnight at 37°C and subsequently heat-inactivated for 30 min at 56°C. Next, two-fold serially diluted sera were incubated with the same volume (25 μL) of PR8 virus (4 HAU) for 1 h at 37°C. Fifty microliters of chicken red blood cells were added and incubated for 1 h at 4°C. HI antibody titers were expressed as the highest serum dilution factor that completely inhibited hemagglutination. For PRNT, sera were heat-inactivated for 30 min at 56°C, and two-fold serially diluted sera were incubated with 100 PFU of PR8 viruses for 90 min at 37°C. The mixtures were subjected to plaque assay on MDCK cells, and cells were incubated at 37°C in a 5% CO_2 incubator until plaques became visible. PRNT_50 titers were expressed as the serum dilution factor that resulted in 50% plaque reduction compared to the control.

ADCC Assay

ADCC activity in mouse sera was estimated using the ADCC assay kit (mFcRIV ADCC Reporter Bioassay, Promega, Madison, WI, U.S.). MDCK cells cultured on 96-well white plates were incubated with 10^5 PFU of PR8 virus for 45 min at 37°C. After washing, the plates were incubated at 37°C in a 5% CO_2 incubator overnight with trypsin-supplemented MEM. After washing, diluted mouse sera and effector cells (genetically engineered Jurkat T cell line that expresses mouse FCγRIV receptor and a luciferase reporter driven by an NFAT response element) were added to the infected cells, and the plates were incubated at 37°C in a 5% CO_2 incubator for 6 h. Subsequently, luciferase reagent was added, and relative luminescence units (RLU) were detected using a spectrophotometer. Fold induction was calculated using the following formula: fold induction = RLU (induced – background)/RLU (no antibody control – background).

Statistical Analysis

All experiments were conducted once, except for the purpose of evaluating the statistical significance. All data are expressed as means and scatter plots or error bars. Error bars indicate standard deviations (SD). Student's t-test was used to compare two different groups. One-way ANOVA followed by Tukey's multiple comparison test was conducted to compare three or more groups. Repeated measures two-way ANOVA followed by Bonferroni's post-test was used to analyze weight changes for different mouse groups over time. Survival rate data were analyzed by log-rank (Mantel-Cox) test, but they were not statistically significant. Differences were considered statistically significant when P < 0.05 (**P < 0.01; *P < 0.05).

RESULTS

Adjuvant Effects of GT or EGCG in Combination With HA Antigen

To examine the adjuvant effect of catechins, 4 μg of recombinant full-length HA was coadministered with GT or EGCG (Figure 1A) into mice, and the immunogenicity and protective efficacy of the vaccine were evaluated. Alum-adjuvanted HA was used as a control. The vaccination was repeated thrice with an interval of 2 weeks (Figure 1B). Sera were collected from the mice two weeks after the last vaccination to measure serum antibody titers. Mice administered HA without any adjuvant poorly induced serum IgG antibodies, and only one out of five mice generated detectable antibodies (Figure 1C). In contrast, robust antibodies were induced by alum, GT, and EGCG. While alum-adjuvanted HA induced the highest ELISA antibody titer of 2111, GT- and EGCG-adjuvanted HA generated antibody titers of 800 and 606, respectively. Viral HA inhibitory antibodies were considerably increased by the use of alum, GT, or EGCG compared with non-adjuvanted HA (Figure 1D). Alum and GT resulted in similar levels of PRNT_50 neutralizing antibody titers; EGCG also led to a moderate increase in neutralizing antibodies compared to non-adjuvanted HA (Figure 1E). These results suggest that GT and EGCG enhanced neutralizing antibody generation although their potency was slightly weaker than that of alum. To assess the protective efficacy of the vaccination, vaccinated mice were challenged with 2 MLD_50 (mouse lethal dose 50) of wild-type PR8 virus 3 weeks after the last vaccination. This challenge was lethal to non-vaccinated mice. Vaccination with non-adjuvanted HA resulted in ~10% weight loss and provided only partial protection in mice; two out of five mice succumbed following the challenge (Figure 1F). Conversely, alum, GT, and EGCG caused only mild weight loss and provided complete protection against lethal challenges. Although the survival rate data were not statistically significant (analyzed by log-rank test), the weight changes showed that the mice given the GT- and EGCG-adjuvanted HA were significantly less susceptible to the challenge. Taken together, our results demonstrate that GT and EGCG exhibit strong adjuvant effects by increasing the neutralizing antibody titers and protective efficacy.

Adjuvant Effect of GT or EGCG on HA GD Antigen

The HA GD harbors the receptor-binding site and is, thus, the most important vaccine antigen for inducing neutralizing
antibodies. Recombinant GD antigens, comprising the HA1 domain, were produced from *E. coli* (36) and coadministered with GT or EGCG into mice to evaluate the antibody response and protective efficacy of adjuvanted GD antigens. Compared with non-adjuvanted GD vaccine, alum-, GT-, and EGCG-adjuvanted GD vaccines induced 2, 6, and 1.5 times higher ELISA IgG antibodies, respectively (Figure 2A). Similar levels of HI antibody titers were observed for the three antigens, which were higher than those from the non-adjuvanted GD group (Figure 2B). While non-adjuvanted GD vaccine did not induce detectable PRNT<sub>50</sub> neutralizing antibodies, GT- and EGCG-adjuvanted GD vaccines induced detectable PRNT<sub>50</sub> neutralizing antibodies although their antibody titers were lower than that for alum-adjuvanted GD vaccine (Figure 2C). The vaccinated mice were challenged with 2 MLD<sub>50</sub> of the wild-type PR8 virus to evaluate the protective efficacy of the vaccines. Vaccination with non-adjuvanted GD exhibited poor protection against the challenge, resulting in considerable morbidity and mortality (Figure 2D). Vaccination with alum- or EGCG-adjuvanted GD demonstrated a similar degree of partial protection, resulting in a survival rate of 60% following the challenge. GT-adjuvanted GD vaccine showed the most robust protection in terms of morbidity and mortality, without causing any death in mice. Overall, it appeared that the GD antigen was less immunogenic than full-length HA (Figure 1). Although the survival rate analyzed by log-rank test did not reach statistical significance, the weight changes showed that the mice given the GT or EGCG-adjuvanted GD were significantly less susceptible to the challenge. Thus, the combination of GT or EGCG with GD antigen improved the protective efficacy, reflected by attenuation of weight loss and mortality from lethal infection.

### Dose-Dependent Adjuvanticity of EGCG

Based on the results that full-length HA antigens showed higher immunogenicity than GD, the dose-dependent adjuvanticity of EGCG was investigated using HA antigens as a vaccine. Three different doses of EGCG (70, 350, or 700 µg) were mixed with 7 µg of HA antigens and injected into mice thrice at the intervals of 2 weeks, and sera were collected after each vaccination to measure antibody responses (Figure 3A). After the third vaccination, dose dependence was clear in all criteria of immunogenicity, including ELISA, HI, and PRNT<sub>50</sub> antibodies. The use of 70 µg of EGCG led to slightly higher levels of ELISA, HI, and PRNT<sub>50</sub> antibodies than non-adjuvanted vaccine; however, the difference was not statistically significant (Figures 3B–D). Higher doses (350 µg and 700 µg) of EGCG resulted in more apparent increases in antibody titers. Compared with the non-adjuvanted vaccine, 700 µg of EGCG induced

---

**FIGURE 2** | Adjuvant effect of GT or EGCG on recombinant HA GD antigen. PBS or 10 µg of GD antigens with or without alum, GT, or EGCG were injected into mice via IM route thrice with the interval of two weeks. The overall experimental schedule was the same as presented in Figure 1B. (A) IgG antibody response to influenza PR8 virus. The antibody titer of each sample was expressed as the endpoint dilution with an absorbance value 2× greater than that of the PBS control group. The detection limit (dashed line) was 100. (B, C) Neutralizing antibody responses to influenza PR8 virus. HI antibody titers (B) and PRNT<sub>50</sub> titers (C) against the PR8 virus are shown. The detection limits of the HI assay and PRNT (dashed lines) were 8 and 50, respectively. (D) Protective efficacy against influenza PR8 virus. The vaccinated mice were challenged with 2 × 10<sup>3</sup> PFU (2 MLD<sub>50</sub>) of wild type PR8 virus after the last vaccination, and the changes in weight and survival rates of the mice were monitored. Dashed line indicates humane endpoint which means losing 25% weight loss. Mice that lost >25% body weight were euthanized. Data of antibody titers (A–C) were log-transformed and expressed as means (horizontal lines) and scatter plots. Data of the changes in weight (D, left panel) are shown as means (points) and standard deviations (error bars). Repeated measures two-way ANOVA followed by Bonferroni’s post-test was used to analyze weight changes for different mouse groups over time. Each group was compared with the group given the non-adjuvanted GD (**P < 0.01; *P < 0.05).
FIGURE 3 | Dose-dependent adjuvanticity of EGCG. PBS or 7 µg of HA antigens with or without adjuvant (70, 350, or 700 µg of EGCG) were injected into mice via IM route thrice every 2 weeks. (A) Vaccination, blood collection, and challenge schedule. (B) IgG antibody response to influenza PR8 virus. The antibody titer of each sample was expressed as the endpoint dilution with an absorbance value 2x greater than that of the PBS control group. Data were log-transformed and expressed as means (horizontal lines) and scatter plots. The detection limit (dashed line) was 400. (C, D) Neutralizing antibody responses to influenza PR8 virus. HI antibody titers (C) and PRNT<sub>50</sub> titers (D) against the PR8 virus. Data were log-transformed and expressed as means (horizontal lines) and scatter plots. The detection limits of the HI assay and PRNT (dashed lines) were 8 and 25, respectively. (E) IgG antibody response to influenza PR8 virus depending on the number of vaccine doses. Data were log-transformed and expressed as means (bar graphs) and standard deviations (error bars). The detection limit (dashed line) was 400. (F) Neutralizing antibody responses to influenza PR8 virus depending on the number of vaccine doses. Data were log-transformed and expressed as means (bar graphs) and standard deviations (error bars). The detection limit (dashed line) was 25. (G) Protective efficacy against influenza PR8 virus. The vaccinated mice were challenged with 4 × 10<sup>3</sup> PFU (4 MLD<sub>50</sub>) of influenza PR8 virus after the last vaccination. Dashed line indicates humane endpoint which means losing 25% weight loss. Mice that lost >25% body weight were euthanized. Data of the changes in weight (G, left panel) are shown as means (points) and standard deviations (error bars). Student’s t-test was used to compare two different groups. One-way ANOVA followed by Tukey’s multiple comparison test was conducted to compare three or more groups. Repeated measures two-way ANOVA followed by Bonferroni’s post-test was used to analyze weight changes for different mouse groups over time. Each group was compared with the group given the non-adjuvanted HA ("**P < 0.01; *P < 0.05, ns, not significant).
significantly higher levels of ELISA (×24), HI (×11), and PRNT<sub>50</sub> (×14) antibodies, showing a clear dose-dependent increase in adjuvanticity. Serum antibody titers after each vaccination with or without 700 µg EGCG were also compared. The non-adjuvanted HA vaccine induced detectable ELISA antibodies and neutralizing antibodies only after the third vaccination (Figures 3E, F). In contrast, only two doses of 700 µg EGCG with HA were able to generate detectable levels of ELISA antibodies and neutralizing antibodies. Of note, the ELISA antibody titer elicited by the second dose of EGCG-adjuvanted HA vaccine was higher than that elicited by the third vaccination with the non-adjuvanted HA vaccine (Figure 3E). Neutralizing antibody titers were similar between the second dose of EGCG-adjuvanted HA vaccine and the third dose of non-adjuvanted HA vaccine (Figure 3F), suggesting robust immune-stimulating potency of EGCG. The vaccinated mice were challenged with 4 MLD<sub>50</sub> of the wild-type PR8 virus to examine their protective efficacy. Mice vaccinated with non-adjuvanted HA displayed a weight loss of ~5% and were partially protected after the challenge (Figure 3G). However, EGCG-adjuvanted HA vaccines provided complete protection against the challenge without causing weight loss and mortality even at the lowest dose of EGCG (Figure 3G). Although the survival rate data were not statistically significant, the weight changes showed that EGCG, even at the lowest concentration used, significantly contributed to protective immune responses.

Characterization of Serum IgG Antibody Subclass and ADCC Activity Elicited by EGCG-Adjuvanted HA Vaccine

Murine IgG antibodies are divided into four subclasses based on the differences in their structures and functions: IgG1, IgG2a, IgG2b, and IgG3 (38). Importantly, it has been shown that IgG2a has the highest affinity toward Fcγ receptors on the surface of effector immune cells; thus, it activates antibody effector functions (18, 39, 40). IgG1 and IgG2a antibody titers induced by alum- or EGCG-adjuvanted HA vaccine were compared by ELISA. While vaccination with non-adjuvanted HA induced
high levels of IgG1 antibodies, the addition of alum or EGCG to the vaccine further increased the level of IgG1 antibodies (4-6 fold). (Figure 4A). However, no detectable IgG2a antibodies were induced by the non-adjuvanted or alum-adjuvanted HA vaccine (Figure 4B). Notably, EGCG dramatically increased IgG2a antibodies in a dose-dependent manner, producing >37× higher antibody titers (at 700 µg dose) than alum. Similarly, potent induction of IgG2a antibodies by EGCG was also observed when recombinant HA GD (Figure 4C) or HA ST (stalk domain mostly comprising HA2 domain) (Figure 4D) was used as a coating antigen. Remarkably, while the increase in IgG1 level was only marginal (4 fold), the increase in IgG2a level was approximately >300-700 fold in EGCG-adjuvanted HA vaccine (Figures 4C, D). These results show that the EGCG-adjuvanted HA vaccine induced balanced IgG2a/IgG1 antibodies (IgG2a/IgG1 ratio = approximately 0.44–0.87), whereas the non-adjuvanted HA vaccine displayed only a skewed value of IgG2a/IgG1 ratio, approximately 0.004–0.036 (Figure 4E).

To examine whether antibodies induced by the vaccines have antibody effector functions, an ADCC assay was performed on the sera. Compared with non-adjuvanted HA vaccine which poorly induced ADCC activities, alum-adjuvanted HA vaccine led to a moderate increase in ADCC activity; however, this increase was not statistically significant (Figure 5). Furthermore, 70 µg of EGCG resulted in similar ADCC activities to alum and 350 µg of EGCG induced approximately 4 fold higher ADCC activities but did not show statistical significance. The strong induction of ADCC effector function was observed upon administration of 700 µg of EGCG-adjuvanted HA vaccine, commensurate to 14.1 and 9.5 fold increase observed for non-adjuvanted and alum-adjuvanted vaccine, respectively. A strong correlation was noted between the ADCC activities among vaccination groups and IgG2a antibody titers (Figures 4B, 5), suggesting that IgG2a antibodies are primarily responsible for ADCC activity (39, 40). A dramatic isotype switching correlated with ADCC function, which is not expected in adjuvanted vaccines.

Synergistic Effect of EGCG and Alum

Several adjuvants consist of two or more components as immune-stimulating materials in the particulate form (3). Therefore, we examined whether the combined use of EGCG and alum can generate synergistic effects on the immunogenicity of the HA antigen. As the order of mixing the components may affect the immunogenicity, two different methods of combining alum and EGCG with HA antigens were compared: 1) (HA + EGCG) + alum (HA proteins were first mixed with EGCG and then alum was added to the mixture) and 2) (HA + alum) + EGCG (HA proteins were first mixed with alum and then EGCG was added to the mixture). Compared with non-adjuvanted HA, alum and EGCG increased ELISA IgG antibodies, but the increase was not significant (Figure 6A). However, for both the formulations, a significant increase in ELISA antibodies was observed, with the first formulation inducing higher antibody titers than the second. Neutralizing H1 and PRNT50 antibodies showed very similar patterns to ELISA antibody titers among the vaccination formulations. The combination of EGCG and alum induced higher levels of neutralizing antibodies than their individual administration, and while there was no statistical significance, the (HA + EGCG) + alum formulation consistently showed higher potency than the (HA + alum) + EGCG formulation (Figures 6B, C). Thus, results suggest that EGCG and alum synergistically enhance neutralizing antibody responses of HA, and the mixing order may influence the immunogenicity. Serum antibody titers after each vaccination with or without adjuvant were also compared (Figures 6D, E). The ELISA and neutralizing antibody titers of the second dose in combination of EGCG and alum were comparable to those of the third dose without combination, demonstrating a dose-sparing effect. The protective efficacy of all adjuvanted HA vaccines was complete without causing any morbidity following the lethal challenge in mice (Figure 6F), suggesting that EGCG alone or in combination with alum induced neutralizing antibodies sufficient for protection.

Adjuvant Effect of EGCG to Other Types of Vaccine

Given that most of the currently licensed inactivated viral vaccines are formalin-inactivated, the adjuvanticity of EGCG was investigated using FAiV. FAiV was injected into mice twice at an interval of 3 weeks with or without EGCG for comparison of
antibody responses between the two groups (Figure 7A). Co-administration of EGCG with FAiV induced three to four times higher levels of serum total IgG, IgG1, and IgG2a antibodies than that of FAiV-only group (Figure 7C). Likewise, a higher level of neutralizing antibodies was induced when EGCG was co-administered with FAiV, but the difference was not statistically significant. Next, the adjuvanticity of EGCG was also tested using a commercial quadrivalent influenza split vaccine containing four antigens derived from A/Singapore/GP1908/2015 IVR-180 (H1N1), A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2), B/Phuket/3073/2013, and B/Maryland/15/2016 NYMC BX-69A. The split vaccine with or without EGCG was injected once into mice, and sera were collected 3 weeks after vaccination to measure the antibody response (Figure 7B). ELISA assays using influenza viruses as coating antigens revealed generation of >2–8× higher levels of IgG antibodies against a variety of viruses, including A/Seoul/Y-1/2009 (H1N1), A/Philippines/2/82 (H3N2), B/Shanghai/361/2002 (B/Yamagata lineage), and B/Brisbane/60/2008 (B/
Victoria lineage) strains (Figure 7D). These results clearly indicate that EGCG can improve the immunogenicity of inactivated viral vaccine and seasonal quadrivalent split vaccine in addition to the recombinant protein vaccine (Figures 1, 3), demonstrating the versatility of EGCG as a novel vaccine adjuvant.

**DISCUSSION**

This study presents EGCG as a novel vaccine adjuvant for viral vaccines. Although GT also had an adjuvant effect as shown in Figures 1, 2, it was not further pursued in the present study, considering potential variations of its chemical composition, which could pose difficulties for quality control. The effect of EGCG was proven for both recombinant HA [full-length or GD comprising receptor-binding domain from bacterial host (36, 41)] and virus-derived HA (inactivated split vaccine). HA antigens without adjuvants poorly induced neutralizing antibodies and provided only partial protection against lethal challenge in mice. In contrast, the coadministration of EGCG with HA antigens resulted in robust virus-specific ELISA responses and neutralizing antibodies, providing complete

![Diagram](image-url)
protection against the challenge. Recombinant protein antigens are usually poorly immunogenic because of their small size. The oligomeric assembly of monomeric antigens in a highly repetitive manner (as VLPs or nanoparticles) is the key to activate B-cells (42–44). Thus, particulate formation and/or adjuvant usage with antigens is crucial for improving the immunogenicity of subunit vaccines (45). EGCG has been shown to induce protein multimerization (46, 47) and cross-link with viral antigens mainly through sulphhydryl linkages (35). EGCG is an aromatic compound comprising a large number of hydroxyl groups with the ability to interact with protein antigens via multiple hydrogen bonds, aromatic stacking, and hydrophobic interactions. It is possible that the EGCG-induced multimerization of monomeric antigens into larger particulate forms may enable their uptake by antigen-presenting cells (45, 46). In addition to multimerization, there may be some other effects that improve the immunogenicity of vaccines. The molecular mechanisms underlying the immune-stimulating activity of EGCG other than antigen multimerization remain unclear although naturally observed EGCG derivatives have recently been shown to activate TLR-5 (48). It should also be mentioned that while EGCG was able to improve the immunogenicity of recombinant proteins and inactivated vaccines, it either slightly affected or reduced the antibody response of HPV VLPs (Supplementary Figure S1), probably due to interfering with the physical integrity of VLPs. It is likely that the same type of interactions (hydrophobic or H-bond) between EGCG and the target protein may have a beneficial effect by increasing the immunogenicity of monomeric soluble antigens by their multimerization or prove detrimental for VLP vaccines by interfering with the regular assembly of viral antigens. Thus, a judicious choice of vaccine type and compatibility of the vaccine manufacturing process is required for the best application of EGCG as a vaccine adjuvant.

Antibody effector functions such as ADCC, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity provide additional correlates of protection in addition to direct neutralization by antibodies, improving the potency and breadth of protection (49–52). It has been shown that the induction of antibody effector functions by adjuvants translates into improved vaccine efficacy (53, 54). In particular, antibody effector functions have emerged as critical correlates of protection for the development of broadly protective universal influenza vaccines (55–57). Our data suggest that EGCG is a novel vaccine adjuvant that can induce ADCC-mediating antibodies. While alum induced an antibody response dominated by IgG1 antibodies, EGCG robustly induced IgG2a as well as IgG1 antibodies that correlated with ADCC activity (Figures 4A, B, 5). These results are consistent with the more potent character of IgG2a for the FcyR-mediated effector functions (39, 40, 58). It would be worthwhile to examine whether EGCG-exerted effector function would impart broader protection against heterologous influenza viruses through further studies (56, 57). In mice, IgG1 and IgG2a antibody responses represent $T_{H2}$ and $T_{H1}$ immune responses, respectively (59). Considering that the balanced induction of $T_{H1}/T_{H2}$ immune response is a highly desirable trait for the development of novel vaccine adjuvants (2, 60), EGCG provides an option for the induction of antibody-mediated neutralizing and effector functions.

Our data demonstrates a synergistic effect between EGCG and alum. A significant increase in neutralizing antibody levels was observed when HA antigens were combined with both alum and EGCG (Figure 6). Notably, the order in which alum and EGCG were added to the HA antigens influenced the neutralizing antibody titers. We believe that the multimerization of HA proteins by EGCG should precede its adsorption onto alum for optimal immunogenicity of recombinant protein antigens. The synergistic effects of EGCG and alum strongly suggest that EGCG can be compatibly used with alum-adjuvanted currently licensed vaccines for further improvement of vaccine efficacy. For example, the use of AS04 adjuvant comprising alum and MPL in Cervarix, a licensed HPV vaccine, induced robust immune responses (61). Dose-sparing is an important issue in increasing the global supply of vaccines, especially in the case of a pandemic. Thus, the present results are directly relevant to the immediate supply of pandemic influenza vaccines (62, 63). The ongoing COVID-19 pandemic underscores the need for rapid supply of vaccines. The dose-sparing effect of adjuvants could increase the volume of pandemic vaccines in a timely manner. As a representative plant-derived adjuvant, QS-21 is in high demand for the COVID-19 vaccine (25, 26). However, this triterpenoid moiety requires extensive fractionation from high molecular weight saponins with various modifications. In contrast, the catechin EGCG (molecular weight 458 Da) in high purity is easy to supply, making it a suitable, novel biomaterial adjuvant for pandemic vaccines.

While EGCG presents as an option for developing safe and effective vaccines, some issues remain to be addressed for the clinical and practical application of EGCG as a vaccine adjuvant. The present evaluation based on a mouse model should be preferably extended to a ferret challenge with a wide spectrum of antigen dose. Although most of data in this study showed that EGCG-adjuvanted HA were significantly superior to non-adjuvanted HA, the difference in survival rate was not statistically significant presumably by using a very high concentration of HA protein as a comparator, and we plan to address it in the future by repeating the experiments with lower antigen dose. EGCG interferes with the single radial immunodiffusion or ELISA-based assays for quantitative estimation of vaccine antigens (data not shown), requiring an alternative potency assay for the licensure of EGCG-adjuvanted vaccine (64, 65). Moreover, the safety and tolerability of EGCG should be evaluated in the context of vaccine delivery although safety and various types of health benefits of GT as a beverage have been documented. The induction of both humoral immunity and CMI is essential for improved protection. While the present study successfully demonstrated a robust induction of neutralizing antibodies and antibody effector function by EGCG, further studies are required to investigate the molecular mechanisms of adjuvant function and potential cross-protection. Additionally, as reflected in the IgG2a/IgG1 ratio, the choice of
vaccine type needs to be screened for the best application of EGCG as a vaccine adjuvant with respect to modulating antibody effector function. It is also necessary to evaluate the adjuvant effect of EGCG against other vaccine antigens for broader applications. However, the potential of EGCG to improve the immunogenicity and protective efficacy of currently licensed vaccines warrants further investigation. Although this study mainly focuses on using EGCG as an adjuvant, Potent virucidal effects of GT catechins have been previously documented for a variety of viruses (34, 66). Thus, the dual function of EGCG, virucidal and adjuvating, could be used to improve inactivated whole virus/split vaccine as well as for recombinant/subunit vaccines.

In conclusion, this study presents EGCG as a novel adjuvant for subunit, split, and inactivated vaccines. In addition to robust neutralizing antibodies, EGCG induced ADCC-mediated antibodies and balanced T_{H}1/T_{H}2 immunity. As a plant-derived biomaterial, EGCG catechin can serve as a novel adjuvant for the development of safe and effective vaccines with increased public acceptance. The dose-sparing effect of stand-alone or combination of adjuvants will also address vaccine supply issues in pandemic outbreaks.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

REFERENCES

1. Mascola JR, Fauci AS. Novel Vaccine Technologies for the 21st Century. Nat Rev Immunol (2020) 20(2):87–8. doi: 10.1038/s41577-019-0243-3
2. Reed SG, Orr MT, Fox CB. Key Roles of Adjuvants in Modern Vaccines. Nat Med (2013) 19(12):1597–608. doi: 10.1038/nm.3409
3. Schijns VE, Lavelle EC. Trends in Vaccine Adjuvants. Expert Rev Vaccines (2011) 10(4):539–50. doi: 10.1586/erv.11.21
4. Slutter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA. Adjuvant Effect of Cationic Liposomes and CpG Depends on Administration Route. J Control Release (2011) 154(2):123–30. doi: 10.1016/j.jconrel.2011.02.007
5. Weinberger B. Adjuvant Strategies to Improve Vaccination of the Elderly Population. Curr Opin Pharmacol (2018) 41:34–41. doi: 10.1016/j.coph.2018.03.014
6. Apostolico Ide S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: Classification, Modus Operandi, and Licensing. J Immunol Res (2016) 2016:1459394. doi: 10.1155/2016/1459394
7. Walker WT, Faust SN. Monovalent Inactivated Split-Virion A503-Adjuvanted Pandemic Influenza A (H1N1) Vaccine. Expert Rev Vaccines (2010) 9(12):1385–98. doi: 10.1586/erv.10.141
8. James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine. Ann Pharmacother (2018) 52(7):673–80. doi: 10.1177/1060028018758431
9. Kundi M. New Hepatitis B Vaccine Formulated With an Improved Adjuvant System. Expert Rev Vaccines (2007) 6(2):133–40. doi: 10.1586/14760584.6.2.133
10. Oleszynka E, McCluskey S, Sharp FA, Munoz-Wolf N, Hams E, Gorman AL, et al. The Vaccine Adjuvant Alum Promotes IL-10 Production That Suppresses Th1 Responses. Eur J Immunol (2018) 48(4):705–15. doi: 10.1002/eji.201747150

ETHICS STATEMENT

The animal study was reviewed and approved by Institutional Animal Care and Use Committee (IACUC) of the International Vaccine Institute (IVI, Seoul, Republic of Korea).

AUTHOR CONTRIBUTIONS

YC and BS designed the study. YC, JA, SB, YJ, and BS analyzed the data and wrote the manuscript. YC performed overall experiments. MK, HO, JL, and WC performed animal experiments. SY, MSK, and JY provided recombinant protein antigens and technical assistance. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported in part by Brain Korea 21 (BK21) FOUR program and National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science, ICT and Future Planning), grant number 2020R1A2C1010703.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.769088/full#supplementary-material

11. Claudi AL, Merkley SA, Carpenter JF, Randolph TW. Inhibition of Aggregation of Aluminum Hydroxide Adjuvant During Freezing and Drying. J Pharm Sci (2008) 97(6):2049–61. doi: 10.1002/jps.21143
12. Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, et al. MF59 Emulsion is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020). Pharm Res (2009) 26(6):1477–85. doi: 10.1007/s11095-009-9859-5
13. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, et al. Combination Adjuvants for the Induction of Potent, Long-Lasting Antibody and T-Cell Responses to Influenza Vaccine in Mice. Vaccine (2008) 26(4):552–61. doi: 10.1016/j.vaccine.2007.11.054
14. Burchill MA, Tamburini BA, Pennock ND, White JT, Kurche JS, Kedl RM. T Cell Vaccinology: Exploring the Known Unknowns. Vaccine (2013) 31(2):297–305. doi: 10.1016/j.vaccine.2012.10.096
15. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. (2012).
16. Kawasaki Y, Suzuki J, Sakai N, Iosem M, Nozawa R, Tani J, et al. Evaluation of T Helper-1/2 Balance on the Basis of IgG Subclasses and Serum Cytokines in Children With Glomerulonephritis. Am J Kidney Dis (2004) 44(1):42–9. doi: 10.1053/ajkd.2004.03.029
17. Romagnani S. Biology of Human TH1 and TH2 Cells. J Clin Immunol (1999) 19(3):121–9. doi: 10.1007/BF01954310
18. Iqbalaskanda S, Reading PC, Kent SJ. Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza Vaccine. J Immunol (2014) 193(2):469–75. doi: 10.4049/jimmunol.1400432
19. Tamm A, Schmidt RE. IgG Binding Sites on Human Fc Gamma Receptors. Int Rev Immunol (1997) 16(1):57–85. doi: 10.3109/08830199709445703
20. Yam KK, Gupta J, Winter K, Allen E, Brewer A, Beaulieu E, et al. AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice. Front Immunol (2015) 6:207. doi: 10.3389/fimmu.2015.00207

Frontiers in Immunology | www.frontiersin.org November 2021 | Volume 12 | Article 769088
21. Casella CR, Mitchell TC. Putting Endotoxin to Work for Us: Monophosphoryl Lipid A as a Safe and Effective Vaccine Adjuvant. Cell Mol Life Sci (2008) 65 (20):3231–40. doi: 10.1007/s00018-008-8228-6

22. Klinman DM. CpG DNA as a Vaccine Adjuvant. Expert Rev Vaccines (2003) 2 (2):355–15. doi: 10.1586/14760584.2.2.305

23. Soltysek S, Wu YJ, Recchia J, Wheeler DA, Newman MJ, Coughlin RT, et al. Structure/function Studies of QS-21 Adjuvant: Assessment of Triterpene Aldehyde and Glucuronic Acid Roles in Adjuvant Function. Vaccine (1995) 13(15):1403–10. doi: 10.1016/0264-410X(95)00077-E

24. Wiedinger K, Pinho D, Bitsaktsi C. Utilization of Cholera Toxin B as a Mucosal Adjuvant Elicits Antibody-Mediated Protection Against s. pneumoniae infection in mice. Ther Adv Vaccines (2017) 5(1):15–24. doi: 10.1177/2051013616691041

25. Sharma R, Palanisamy A, Dhamra M, Mal G, Singh B, Singh KP. Exploring the Possible Use of Saponin Adjuvants in COVID-19 Vaccine. Hum Vaccin Immunother (2020) 16(1):2944. doi: 10.1080/21644551.2020.1833579

26. Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, et al. SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice. Nat Commun (2021) 12(1):372. doi: 10.1038/s41467-020-20653-8

27. Bharucha T, Kogai K, Fujimura Y, Yamada K. A Critical Appraisal of ‘Shingrix’, a Novel Vaccine Against Herpes Zoster Virus. Proc Natl Acad Sci USA (2010) 107(45):19396–401. doi: 10.1073/pnas.1011507107

28. Jang YH, Seong BL. Call for a Paradigm Shift in the Design of Universal Influenza Virus Antigens for Influenza Vaccination. Front Immunol Cell Biol (2020) 14:3686. doi: 10.3389/fimmu.2019.03548

29. Baum LL, Cassutt KJ, Knigge K, Khattry R, Margolick J, Rinaldo C, et al. HIV-1 Gp120-Specific Antibody-Dependent Cell-Mediated Cytotoxicity Correlates With Rate of Disease Progression. J Immunol (1996) 156(5):2137–43. doi: 10.4049/jimmunol.166.12.7381

30. Boudreaux CM, Yu WH, Suscovich TJ, Talbot HK, Alter G. Selective Induction of Antibody Effector Functional Responses Using MF59-Adjuvanted Vaccination. J Immunol (2014) 196:56. doi: 10.7588/jir.2013.09734

31. O'Brien KB, Morrison TE, Dundore DY, Heise MT, Schultz-Cherry S. A Protective Role for Complement C3 Protein During Pandemic 2009 H1N1 and H5N1 Influenza A Virus Infection. PloS One (2011) 6(3):e17377. doi: 10.1371/journal.pone.0017377

32. Datta A, Datta D, Dutta S, Das P. A Novel Vaccine for the Treatment of Human Hepatitis C Virus Infection. Expert Opin Ther Targets (2021) 25(6):467–77. doi: 10.1080/14728222.2020.1803629

33. Li Y, Zang H, Wang M, Wang H, Wang J, Shao X, et al. Low-Pathogenic Avian Influenza Virus H9N2 Adjuvant Evaluation. Microb Pathog (2020) 143:104138. doi: 10.1016/j.micpath.2020.104138

34. Sarvas HO, Seppala IJ, Tahtinen T, Peterfy F, Makela O. Mouse IgG As a Method for Removing Bacterial Endotoxin From Antibody Preparations. Biotechnol Prog (2014) 30(6):1497–501. doi: 10.1002/btp.1961

35. Jang YH, Seong BL. Call for a Paradigm Shift in the Design of Universal Influenza Virus Antigens For Influenza Vaccination. Expert Opin Ther Targets (2021) 25(6):467–77. doi: 10.1080/14728222.2020.1803629

36. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Require FcgammaRI Interactions for Protection Against Influenza Virus In Vivo. Nat Med (2014) 20(2):143–51. doi: 10.1038/nm.3443

37. DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly Neutralizing Anti-Influenza Antibodies Require Fc Receptor Engagement for In Vivo Protection. J Clin Invest (2016) 126(2):605–10. doi: 10.1172/JCI84428

38. Collins AM. IgG Subclass Co-Expression Brings Harmony to the Quartet Model of Murine IgG Function. Immunol Cell Biol (2016) 94(10):949–54. doi: 10.1038/icb.2016.65

39. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, et al. Regulation of Antibody Isootype Secretion by Subsets of Antigen-Specific Helper T Cells. Nature (1988) 334(6179):255–8. doi: 10.1038/334255a0

40. Hjertner B, Bengtsson T, Morein B, Paulie S, Fossum C. A Novel Adjuvant G3 Induces Both Th1 and Th2 Related Immune Responses in Mice After Immunization With a Trivalent Inactivated Split-Virion Influenza Vaccine. Vaccine (2018) 36(23):3340–4. doi: 10.1016/j.vaccine.2018.04.054

41. McKeage K, Romanowski B. AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®): A Review of Its Use in the Prevention of Premalignant Cervical Lesions and Cervical Cancer Causally
Related to Certain Oncogenic HPV Types. *Drugs* (2011) 71(4):465–88. doi: 10.2165/11206820-000000000-00000
62. Yen HL, Webster RG. Pandemic Influenza as a Current Threat. *Curr Top Microbiol Immunol* (2009) 333:3–24. doi: 10.1007/978-3-540-92165-3_1
63. Sutton TC. The Pandemic Threat of Emerging H5 and H7 Avian Influenza Viruses. *Viruses* (2018) 10(9):461–81. doi: 10.3390/v10090461
64. Williams MS. Single-Radial-Immunodiffusion as an *In Vitro* Potency Assay for Human Inactivated Viral Vaccines. *Vet Microbiol* (1993) 37(3-4):253–62. doi: 10.1016/0378-1135(93)90037-5
65. Chae W, Kim P, Hwang BJ, Seong BL. Universal Monoclonal Antibody-Based Influenza Hemagglutinin Quantitative Enzyme-Linked Immunosorbent Assay. *Vaccine* (2019) 37(11):1457–66. doi: 10.1016/j.vaccine.2019.01.068
66. Colpitts CC, Schang LM. A Small Molecule Inhibits Virion Attachment to Heparan Sulfate- or Sialic Acid-Containing Glycans. *J Virol* (2014) 88(14):7806–17. doi: 10.1128/JVI.00896-14

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Cheong, Kim, Ahn, Oh, Lim, Chae, Yang, Kim, Yu, Byun, Jang and Seong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.